Altimmune, Inc. (ALT) Stock Price & How to Invest
Short answer
You can invest in Altimmune (ALT) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Altimmune is a clinical-stage biopharmaceutical company whose value rests almost entirely on pemvidutide, a GLP-1/glucagon dual agonist being developed for obesity and MASH (a serious fatty-liver disease). The single biggest risk is that outcomes are binary: a Phase 3 miss or regulatory setback could sharply reduce the stock, since the company has no approved product or product revenue.
ALT stock price
As of 2026-06-26, Altimmune, Inc. (ALT) last closed at $2.82, down 19.4% over the past year. Over the past 52 weeks it has traded between $2.59 and $6.18.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Altimmune, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Altimmune, Inc. (ALT) do?
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo.
The company generates no product revenue and funds itself through cash raised in the capital markets. Management planned to advance pemvidutide into a multinational Phase 3 MASH trial (PERFORMA) in the second half of 2026. As a single-asset, pre-commercial biotech, Altimmune's prospects hinge on clinical readouts, regulatory decisions, its cash runway, and whether it can differentiate in a GLP-1 obesity market dominated by much larger competitors.
What's driving Altimmune, Inc. (ALT)?
Differentiated GLP-1/glucagon profile
Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. In the IMPACT MASH trial, the 1.8 mg dose showed about 7.5% weight loss alongside large reductions in liver fat.
MASH opportunity
The Phase 2b IMPACT trial hit key 48-week measures, with statistically significant improvements in noninvasive fibrosis markers versus placebo, supporting a planned Phase 3. MASH is a large, newly addressable market with few approved therapies.
Large obesity market
The GLP-1 obesity market is enormous and still expanding, so even a modest share for a differentiated entrant could be valuable. Pemvidutide targets both obesity and MASH, giving Altimmune two shots on goal from one molecule.
Funded for near-term milestones
Altimmune reported about $535 million in cash, equivalents, and short-term investments in Q1 2026, a substantial runway for a company its size that supports advancing pemvidutide toward Phase 3.
What are the risks to Altimmune, Inc. (ALT)?
Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders.
How is Altimmune, Inc. (ALT) valued? (approximate, Q1 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Altimmune, Inc.'s investor relations page or your broker.
- Product revenue: None (clinical-stage)
- Cash + short-term investments: ~$535 million
- Lead program: Pemvidutide (obesity, MASH)
- MASH stage: Phase 3 (PERFORMA) planned H2 2026
- Valuation basis: Pipeline / clinical optionality
As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. The roughly $535 million cash position is a key strength because it funds expensive Phase 3 work, but the eventual value depends on trial outcomes and approval, both of which are uncertain.
Who competes with Altimmune, Inc. (ALT)?
GLP-1 obesity leaders
Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) dominate the obesity market with approved, blockbuster drugs and far larger resources than Altimmune.
Obesity and MASH biotechs
Companies such as Viking Therapeutics, Madrigal Pharmaceuticals (approved MASH drug), and other metabolic-disease developers compete for the same indications and investor attention.
Emerging dual/triple agonists
A growing field of next-generation GLP-1-based combination agonists from both large pharma and biotech raises the competitive bar for differentiation.
How to invest in Altimmune, Inc. (ALT)
There are three common ways to get ALT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ALT sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ALT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Altimmune, Inc. (ALT)
Altimmune is a one-asset story: pemvidutide's data in MASH and obesity determines almost everything. If you believe its weight-loss-plus-liver profile can carve out a niche against far larger GLP-1 rivals, the question becomes how much binary clinical risk you want and how to size it, not timing. The risk is that a single failed trial or a financing crunch can erase much of the value, and the company competes against Novo Nordisk and Eli Lilly with a fraction of their resources.
More on Altimmune, Inc. (ALT)
Whether ALT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALT a buy?, and where the stock could go from here in the ALT stock forecast.
For income investors, whether ALT pays a dividend and how the payout looks is covered in does ALT pay a dividend?
Build a basket around ALT with Walnut
Use Altimmune, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ALT a good stock to buy right now?
+
It depends on your risk tolerance. Bulls cite positive Phase 2b MASH data, a differentiated weight-loss profile, and a strong cash position. Bears note it is a single-asset, pre-revenue biotech facing binary Phase 3 risk and giant competitors. ALT suits investors who accept high volatility and possible total loss, not conservative buyers. This is not investment advice.
What does Altimmune do?
+
Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual agonist, for obesity and MASH (metabolic dysfunction-associated steatohepatitis, a serious fatty-liver disease). It has no approved products and is focused on advancing pemvidutide through clinical trials toward potential regulatory approval.
What is pemvidutide?
+
Pemvidutide is Altimmune's lead drug candidate, a once-weekly injectable that activates both the GLP-1 and glucagon receptors. It is designed to produce weight loss while preserving lean muscle mass and improving liver health, and is being studied in both obesity and MASH, where it reported positive Phase 2b results.
Is ALT profitable?
+
No. Altimmune is a clinical-stage company with no approved products and no product revenue, so it operates at a loss as it funds research and development. It relies on its cash reserves, about $535 million in Q1 2026, and may raise additional capital to fund pemvidutide's lengthy and costly development.
Does ALT pay a dividend?
+
No. Altimmune does not pay a dividend. Like most clinical-stage biotech companies, it reinvests all available capital into drug development and preserves cash to fund trials, so any return to shareholders would come only from share-price appreciation, not income.
What are the next catalysts for ALT?
+
The key catalyst is the planned PERFORMA Phase 3 MASH trial, which management targeted to begin in the second half of 2026, along with any further obesity program updates. Phase 3 design, enrollment, and eventual readouts, plus potential partnership news, are the events most likely to move the stock.
Who are Altimmune's competitors?
+
In obesity, Altimmune competes with GLP-1 leaders Novo Nordisk and Eli Lilly, plus biotechs like Viking Therapeutics. In MASH, Madrigal Pharmaceuticals already has an approved therapy. The competitive landscape is crowded and well-funded, which raises the bar for pemvidutide to stand out.
Why is ALT stock so volatile?
+
Altimmune's value depends almost entirely on pemvidutide's clinical and regulatory progress, so the stock swings sharply on trial data, conference presentations, and competitor news. Single-asset, pre-revenue biotechs are inherently volatile because each readout can dramatically change the company's prospects.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Altimmune, Inc.'s investor relations page or your broker before making investment decisions.